

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	121	514/391	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:56
L3	6	I2 and (aminosulfonyl)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:57
L4	56	548/320.1	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:57
L5	2	I4 and aminosulfonyl	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:58
L6	432	560/129	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:58
L7	2	I6 and aminosulfonyl	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:58
L8	10	560/303	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/05/09 10:58

10560281final

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:02:27 ON 09 MAY 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:02:41 ON 09 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 MAY 2007 HIGHEST RN 934461-15-1

DICTIONARY FILE UPDATES: 8 MAY 2007 HIGHEST RN 934461-15-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560281d.str



chain nodes :

12 13 14 15

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

Karen Cheng

10560281final

ring/chain nodes :

16

chain bonds :

6-7 8-12 10-14 11-13 14-15 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-12 9-10 10-11 10-14 11-13
15-16

exact bonds :

14-15

isolated ring systems :

containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 10:03:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 82 TO ITERATE

100.0% PROCESSED 82 ITERATIONS

45 ANSWERS

SEARCH TIME: 00.00.01

L2 45 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

Karen Cheng

10560281final

	ENTRY	SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 10:03:53 ON 09 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2007 VOL 146 ISS 20
FILE LAST UPDATED: 8 May 2007 (20070508/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2

L3 2 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:117378 CAPLUS
 DOCUMENT NUMBER: 144:192253
 TITLE: Preparation of imidazolidine derivatives as androgen receptor antagonists
 INVENTOR(S): Tachibana, Kazutaka; Sato, Haruhiko; Ohta, Masateru; Nakamura, Mitsuki; Shiraishi, Takuya; Imaoka, Ikuhiro; Yoshino, Hitoshi; Nagamuta, Masahiro;
 Kawata, Hiromitsu
 PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013887	A1	20060209	WO 2005-JP14195	20050803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1775289	A1	20070418	EP 2005-768418	20050803
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: JP 2004-227321 A 20040803				
WO 2005-JP14195 W 20050803				

OTHER SOURCE(S): MARPAT 144:192253
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [n = 1-20; Q = Q1, Q2; A = cyano, CO2R3, CONR3R4, etc.; B = H, halo, OR3, etc.; X1, X2 = O, S; m = 0-3; E = alkyl; R1, R2 = H, alkyl, alkylcarbonyl; R3, R4 = H, alkyl; when X1 = O and X2 = S, Q is not 4-cyano-3-trifluoromethylphenyl] were prepared. For example, reaction of compound II, e.g., prepared from 3-chloropropanesulfonamide in 2 steps, with 3-chloro-4-cyanophenylisothiocyanate followed by treatment with HCl afforded compound III. In androgen receptor antagonistic activity assays,

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 the IC50 value of compd. III was 200 nM. Compds. I are claimed useful for the treatment of prostate cancer, prostatomegaly, etc.
 IT 875055-92-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of imidazolidine derivs. as androgen receptor antagonists for treatment of prostate cancer, prostatomegaly, etc.)
 RN 875055-92-8 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




IT 875055-93-9P 875055-94-0P 875055-95-1P
 875055-96-2P 875055-97-3P 875055-98-4P
 875055-99-5P 875056-03-4P 875056-04-5P
 875056-05-6P 875056-06-7P 875056-07-8P
 875056-08-9P 875056-09-0P 875056-18-1P
 875056-19-2P 875056-20-5P 875056-21-6P
 875056-23-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazolidine derivs. as androgen receptor antagonists for treatment of prostate cancer, prostatomegaly, etc.)
 RN 875055-93-9 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-(4-cyano-3-methoxyphenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875055-94-0 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-(4-cyano-2-methyl-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 875055-95-1 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-(4-cyano-2-methyl-5-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875055-96-2 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 875055-97-3 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-(4-cyano-3-methylphenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875055-98-4 CAPLUS
 CN 1-imidazolidinepropanesulfonamide,
 3-(4-cyano-3-ethylphenyl)-5,5-dimethyl-
 4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 875055-99-5 CAPLUS
 CN 1-imidazolidinepropanesulfonamide,
 3-(4-cyano-3-ethylphenyl)-5,5-dimethyl-
 4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-03-4 CAPLUS
 CN 1-imidazolidinepropanesulfonamide,
 3-(4-cyano-3-ethylphenyl)-5,5-dimethyl-4-oxo-2-
 thioxo- (9CI) (CA INDEX NAME)




RN 875056-04-5 CAPLUS
 CN Benzoic acid,
 4-[3-[3-(aminosulfonyl)propyl]-4,4-dimethyl-5-oxo-2-thioxo-1-
 imidazolidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-05-6 CAPLUS
 CN Benamide, 4-[3-[3-(aminosulfonyl)propyl]-4,4-dimethyl-5-oxo-2-thioxo-1-
 imidazolidinyl]- (9CI) (CA INDEX NAME)




RN 875056-06-7 CAPLUS
 CN Benamide, 4-[3-[3-(aminosulfonyl)propyl]-4,4-dimethyl-5-oxo-2-thioxo-1-
 imidazolidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-07-8 CAPLUS
 CN Benzoic acid,
 4-[3-[3-(aminosulfonyl)propyl]-4,4-dimethyl-5-oxo-2-thioxo-1-
 imidazolidinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 875056-08-9 CAPLUS
 CN Benamide, 4-[3-[3-(aminosulfonyl)propyl]-4,4-dimethyl-5-oxo-2-thioxo-1-
 imidazolidinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-09-0 CAPLUS
 CN Benzamide, 4-[3-[3-(aminosulfonyl)propyl]-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 875056-18-1 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-([3-(chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-21-6 CAPLUS
 CN 1-Imidazolidineethanesulfonamide, 3-([3-(chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 875056-23-8 CAPLUS
 CN Acetamide, N-([3-([3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-19-2 CAPLUS
 CN 1-Imidazolidinebutanesulfonamide, 3-([3-(chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 875056-20-5 CAPLUS
 CN 1-Imidazolidinepentanesulfonamide, 3-([3-(chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 811794-10-2P 811794-20-4P 875056-28-3P
 875056-29-4P 875056-33-0P 875056-37-4P
 875056-39-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazolidine derivs. as androgen receptor antagonists for treatment of prostate cancer, prostatomegaly, etc.)
 RN 811794-10-2 CAPLUS
 CN Carbamic acid, [[3-([3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 811794-20-4 CAPLUS
 CN 1-Imidazolidineethanesulfonamide, 3-([4-cyano-3-(trifluoromethyl)phenyl]-N,N-bis[(4-methoxyphenyl)methyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl)sulfonyl]-N,N-dimethyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 875056-28-3 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-(3-chloro-4-cyanophenyl)-N-[(dimethylamino)methylene]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-29-4 CAPLUS
 CN Carbamic acid, [[3-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl]sulfonyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875056-33-0 CAPLUS
 CN 1-Imidazolidinebutanesulfonamide, 3-(3-chloro-4-cyanophenyl)-N-[(dimethylamino)methylene]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 875056-37-4 CAPLUS
 CN 1-Imidazolidinepentanesulfonamide, 3-(3-chloro-4-cyanophenyl)-N-[(dimethylamino)methylene]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 875056-39-6 CAPLUS
 CN 1-Imidazolidinehexanesulfonamide, 3-(3-chloro-4-cyanophenyl)-N-[(dimethylamino)methylene]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 811793-48-3P 811793-51-8P 811793-64-3P
 811793-67-6P 811793-78-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of imidazolidine deriva. as androgen receptor antagonists for treatment of prostate cancer, prostatomegaly, etc.)

RN 811793-48-3 CAPLUS
 CN 1-Imidazolidinehexanesulfonamide, 3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-51-8 CAPLUS
 CN 1-Imidazolidinehexanesulfonamide, 3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 811793-64-3 CAPLUS
CN 1-Imidazolidinepentanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thio- (9CI) (CA INDEX NAME)




RN 811793-67-6 CAPLUS
CN 1-Imidazolidinebutanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thio- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811793-78-9 CAPLUS
CN 1-Imidazolidinepropanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,5,5-trimethyl-4-oxo-2-thio- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1127346 CAPLUS
DOCUMENT NUMBER: 142:74567
TITLE: Preparation of imidazolidine derivatives as androgen receptor antagonists
INVENTOR(S): Tachibana, Kazutaka; Sato, Haruhiko; Ohta, Masateru; Nakamura, Mitsueki; Shiraiishi, Takuya; Imaoka, Ikunori; Yoshino, Hitoshi; Nagamuta, Masahiro;
Kawata, Hiromitsu
PATENT ASSIGNEE(S): Chugai Sanyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111012	A1	20041223	WO 2004-JP8211	20040611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GM, GN, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1634874	A1	20060315	EP 2004-745805	20040611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 200613583	A1	20060622	US 2005-560281	20051212
PRIORITY APPLN. INFO.: JP 2003-168267 A 20030612				
WO 2004-JP8211 W 20040611				

OTHER SOURCE(S): MARPAT 142:74567
GI




AB 3-[(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-yl]alkanesulfonamides represented by the formula (I) (wherein n is an integer selected among 1 to 20; and R1 and R2 may be the same or different and each represents hydrogen or linear or branched,

Karen Cheng


L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

alkyl) and salts, prodrugs, and solvates thereof are prep. These compounds are useful for the prevention of or treatment of prostatic cancer, prostatic hypertrophy, male pattern alopecia, early sexual maturity, common acne, seborrheic disease, and hypertrichosis. Thus, 2.2 g MeOZCCMe2NH(CH2)3SO2N:CHNMe2 was dissolved in 34 mL THF, treated with 0.21 mL Et3N and 1.71 g 4-cyano-3-trifluoromethylphenyl isothiocyanate, and stirred at room temp. for 2 h to give 71% I (n = 3, NR1R2 = N:CHNMe2) which (2.6 g) was treated with a mixt. of 6 N aq. HCl and 1,4-dioxane under reflux for 1 h to give 70% I (n = 3, R1 = R2 = H) (II). II and I (n = 3, R1 = R2 = H) showed EC50 of 20,000 and >100,000 nM, resp., as androgen receptor agonists, and IC50 of 200 and 600 nM, resp., as androgen receptor antagonists with EC50/IC50 ratio of 100 and >170, resp., in an androgen receptor reporter gene assay using 11A1B2 cells (HeLa cells expressing human androgen receptor). They showed higher EC50/IC50 ratio than Picartamide (0.067) and hydroxyflutamide (0.1) and are expected to be anti-androgen agents without side effects such as development of androgen resistance and/or liver toxicity.
IT 811793-67-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of
3-[(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-yl]alkanesulfonamides derivs. as androgen receptor antagonists)
RN 811793-67-6 CAPLUS
CN 1-Imidazolidinebutanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thio- (9CI) (CA INDEX NAME)




IT 811793-42-7P 811793-48-3P 811793-51-6P
811793-54-1P 811793-57-4P 811793-60-9P
811793-64-3P 811793-68-7P 811793-70-1P
811793-72-3P 811793-73-4P 811793-75-6P
811793-77-8P 811793-78-9P 811793-80-3P
811793-81-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (prepn. of 3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-alkanesulfonamides derivs. as androgen receptor antagonists)
 RN 811793-42-7 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-48-3 CAPLUS
 CN 1-Imidazolidineethanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-51-8 CAPLUS
 CN 1-Imidazolidinehexanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 811793-60-9 CAPLUS
 CN 1-Imidazolidinenonanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-64-3 CAPLUS
 CN 1-Imidazolidinepentanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 811793-54-1 CAPLUS
 CN 1-Imidazolidineheptanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-57-4 CAPLUS
 CN 1-Imidazolidineoctanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 811793-68-7 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-70-1 CAPLUS
 CN 1-Imidazolidinepentanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-72-3 CAPLUS
 CN 1-Imidazolidinehexanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 811793-73-4 CAPLUS
 CN 1-Imidazolidineheptanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-75-6 CAPLUS
 CN 1-Imidazolidineoctanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811793-80-3 CAPLUS
 CN 1-Imidazolidinebutanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-trimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-81-4 CAPLUS
 CN 1-Imidazolidinepentanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-trimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




Karen Cheng

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 811793-77-8 CAPLUS
 CN 1-Imidazolidinenonanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-tetramethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)




RN 811793-78-9 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N,N,5,5-trimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 811794-21-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of
 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-alkanesulfonamides derivs. as androgen receptor antagonists)
 RN 811794-21-5 CAPLUS
 CN 1-Imidazolidinepropanesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-N-[(dimethylamino)methylene]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



IT 811794-10-2P 811794-20-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of
 3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-alkanesulfonamides derivs. as androgen receptor antagonists)
 RN 811794-10-2 CAPLUS
 CN Carbamic acid, [[3-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]propyl]sulfonyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 811794-20-4 CAPLUS


10560281final

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1-Imidazolidinesulfonamide, 3-[4-cyano-3-(trifluoromethyl)phenyl]-
N,N-bis[(4-methoxyphenyl)methyl]-5,5-dimethyl-4-oxo-2-thioxo- (9CI) (CA
INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:
THIS
FORMAT

13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR
RECORD. ALL CITATIONS AVAILABLE IN THE RE